Clinical Trial Update: An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for experimental immunotherapy BMS-986179, studied alone and with nivolumab, in malignant solid tumors; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumor

Drugs mentioned

• BMS-986179 (null)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Malignant Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-04-05